{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DTG%2F3TC",
    "query": {
      "intervention": "DTG/3TC"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 59,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DTG%2F3TC&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T17:10:35.846Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02893488",
      "title": "Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "DTG/ABC/3TC FDC DISPERSIBLE TABLET",
          "type": "DRUG"
        },
        {
          "name": "EPZICOM (ABC/3TC)",
          "type": "DRUG"
        },
        {
          "name": "TIVICAY (DTG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-09-01",
      "completion_date": "2016-11-25",
      "has_results": false,
      "last_update_posted_date": "2017-08-04",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02893488"
    },
    {
      "nct_id": "NCT04900038",
      "title": "A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3640254",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine capsules",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2021-08-18",
      "completion_date": "2023-05-11",
      "has_results": true,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 8,
      "location_summary": "Bakersfield, California • Palm Springs, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04900038"
    },
    {
      "nct_id": "NCT06393387",
      "title": "Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hiv",
        "HIV-1-infection",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG/3TC versus BIC/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Midway Specialty Care Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2024-06-01",
      "completion_date": "2025-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 1,
      "location_summary": "West Palm Beach, Florida",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06393387"
    },
    {
      "nct_id": "NCT04302896",
      "title": "Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Medication Adherence",
        "HIV"
      ],
      "interventions": [
        {
          "name": "dolutegravir oral tablet 50mg",
          "type": "DRUG"
        },
        {
          "name": "emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg",
          "type": "DRUG"
        },
        {
          "name": "tenofovir disoproxil fumarate oral tablet 300mg",
          "type": "DRUG"
        },
        {
          "name": "lamivudine oral tablet 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rhonda Brand",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-08-31",
      "completion_date": "2021-09-30",
      "has_results": false,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04302896"
    },
    {
      "nct_id": "NCT00951015",
      "title": "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1349572",
          "type": "DRUG"
        },
        {
          "name": "efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2009-07-30",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Long Beach, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00951015"
    },
    {
      "nct_id": "NCT02924389",
      "title": "Dolutegravir in Reservoirs",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Triumeq",
          "type": "DRUG"
        },
        {
          "name": "Truvada",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-09",
      "completion_date": "2019-09-11",
      "has_results": true,
      "last_update_posted_date": "2022-12-29",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02924389"
    },
    {
      "nct_id": "NCT04827134",
      "title": "A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "TRIUMEQ",
          "type": "DRUG"
        },
        {
          "name": "DOVATO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 33,
      "start_date": "2021-05-07",
      "completion_date": "2021-07-23",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04827134"
    },
    {
      "nct_id": "NCT03332095",
      "title": "Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Doravirine (DOR)",
          "type": "DRUG"
        },
        {
          "name": "Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral (ARV) medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 55,
      "start_date": "2018-07-02",
      "completion_date": "2022-05-25",
      "has_results": true,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03332095"
    },
    {
      "nct_id": "NCT02263326",
      "title": "Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Continue current antiretroviral regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Babafemi Taiwo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2014-12",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2019-10-14",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02263326"
    },
    {
      "nct_id": "NCT03945981",
      "title": "Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir + Lamivudine FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2019-07-02",
      "completion_date": "2020-10-20",
      "has_results": true,
      "last_update_posted_date": "2021-10-21",
      "last_synced_at": "2026-09-02T17:10:35.846Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03945981"
    }
  ]
}